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Alessandra Ghigo* and Mingchuan Li
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Torino, Italy
Class I phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases activated by
cell membrane receptors, either receptor tyrosine kinases (RTKs) or G protein–coupled
receptors (GPCRs), to catalyze the production of the lipid second messenger
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). These enzymes engage multiple
downstream intracellular signaling pathways controlling cell proliferation, survival and
migration. In the cardiovascular system, the four class I PI3K isoforms, PI3Ka, PI3Kb,
PI3Kd, and PI3Kg are differentially expressed in distinct cell subsets which include
cardiomyocytes, fibroblasts, endothelial, and vascular smooth muscle cells as well as
leukocytes, suggesting specific functions for distinct PI3K isoenzymes. During the last
decades, genetic disruption studies targeting different PI3K genes have elucidated
the contribution of specific isoenzymes to cardiac and vascular function regulation,
highlighting both beneficial andmaladaptive roles. New layers of complexity in the function
of PI3Ks have recently emerged, indicating that distinct PI3K isoforms are interconnected
by various crosstalk events and can function not only as kinases, but also as scaffold
proteins coordinating key signalosomes in cardiovascular health and disease. In this
review, we will summarize major breakthroughs in the comprehension of detrimental and
beneficial actions of PI3K signaling in cardiovascular homeostasis, and we will discuss
recently unraveled cross-talk and scaffold mechanisms as well as the role of the less
characterized class II and III PI3K isoforms.
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Introduction
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid and protein kinases that primarily function
by catalyzing the phosphorylation of D3 position on the inositol ring of phosphatidylinositols
(PtdIns). Depending on the nature of phosphorylated products, PI3Ks are currently classified into
three classes.
Class I PI3Ks catalyze the production of phosphatidylinositol (3,4,5)-trisphosphate
[PtdIns(3,4,5)P3 or PIP3] from phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P2]. These
enzymes are obligate heterodimers composed by a p110 catalytic subunit among the four identified
p110a, b, g, and d isoforms, and an adaptor subunit of either p85 or p101/p84 family. Class I PI3Ks
can be further subgrouped into class IA and IB, according to the identity of the regulatory subunit
as well as the type of membrane activating receptor. Class IA PI3Ks, PI3Ka, b, and d, associate
with p85 adaptors and are primarily triggered by tyrosine kinase receptors (RTKs), while class
IB PI3Kg binds to either p101 or p84 subunit and has long been considered to respond only to
G protein–coupled receptor (GPCR) agonists (Wymann et al., 2003). However, the classical view
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has been recently modified by the finding that PI3Kb can also
signal downstream of GPCRs (Ciraolo et al., 2008; Guillermet-
Guibert et al., 2008) and p110g can be engaged by RTKs in a
Ras/p84-dependent way (Schmid et al., 2011).
Following class I PI3K activation, PIP3 accumulates at the
plasma membrane and recruits a group of pleckstrin homology
(PH) domain-containing proteins, including phosphoinositide-
dependent kinase-1 (PDK1) and protein kinase B (Akt/PKB).
PIP3-activated PDK1 in turn phosphorylates Akt at Thr308 site
that, together with Ser473 phosphorylation by mammalian target
of rapamycin complex 2 (mTORC2), ensures full Akt activation.
This eventually triggers multiple downstream signaling pathways
involved in protein synthesis, cell proliferation, metabolism and
survival (Franke, 2008).
PI3K activity is counteracted by PTEN (phosphatase and tensin
homolog deleted from chromosome 10), the major endogenous
PI3K inhibitor, which dephosphorylates PIP3 on the D3 position.
PI3Ks and PTEN thus keep the balance of cellular PIP3 levels
that, when deregulated by either amplification of PI3Ks or loss
of PTEN, may lead to dramatic consequences, such as cell
transformation (Cully et al., 2006).
Different from class I, class III includes only one member,
Vps34, which is critically involved in the regulation of vesicular
trafficking and autophagy via PtdIns(3)P generation (Funderburk
et al., 2010). Conversely, little information is available about the
function of class II PI3Ks, including PI3K-C2a, PI3K-C2b and
PI3K-C2g. PI3K-C2a and PI3K-C2g are the best characterized
isoforms and the emerging view is that they also critically
contribute to vesicular trafficking by regulating the production
of PtdIns(3)P (Franco et al., 2014) and PI(3,4)P2 (Braccini et al.,
2015) pools.
Different PI3K isoforms show peculiar expression patterns,
with PI3Ka being ubiquitously expressed and enriched in
cardiomyocytes, and PI3Kg functioning in both leukocytes
and cardiac cells. This implies that distinct PI3K isoenzymes
participate to specific key processes in the maintenance
of cardiovascular homeostasis, including cardiomyocyte
hypertrophy and contractility as well as myocardial and vascular
inflammation (Figure 1). In this review, we will summarize
major breakthroughs in the comprehension of detrimental and
beneficial actions of PI3K isoenzymes in cardiovascular health
and disease, and we will discuss recently unraveled cross-talk and
scaffold mechanisms as well as the role of the less characterized
class II and III PI3K isoforms.
PI3Ka: Essential Role in Cardiac Growth
and Contractility
In the cardiovascular system, PI3Ka is activated by multiple
RTKs. In cardiomyocytes, PI3Ka is engaged by insulin or
insulin-like growth factor-1 (IGF-1) to regulate cardiac growth
and development. Furthermore, fibroblast growth factor (FGF),
platelet-derived growth factor (PDGF) and vascular endothelial
growth factor (VEGF) can activate PI3Ka in endothelial cells,
fibroblasts and vascular smooth muscle cells.
In the last decade, studies based on genetic modified
animals have revealed a critical role for PI3Ka-Akt cascade
in promoting cardiomyocyte postnatal growth and survival.
Cardiac-restricted over-expression of either PI3Ka (Shioi
et al., 2000) or its upstream signaling IGF-1 receptor (IGF1R;
McMullen et al., 2004) results in increased cardiomyocyte
size and larger hearts. In contrast, expression of dominant-
negative p110a or deletion of PI3Ka regulatory subunit p85
leads to reduced heart size (Shioi et al., 2000; Crackower et al.,
2002; Luo et al., 2005) and abolishes IGF1R overexpression-
induced physiological hypertrophy (McMullen et al., 2004).
Consistent with its key role as endogenous PI3K inhibitor,
PTEN inactivation in the heart recapitulates the phenotype
observed in PI3Ka overexpressing animals (Crackower et al.,
2002), suggesting a central role of PI3Ka-dependent PIP3 in
regulating heart growth. Similarly, Akt genetic manipulations
phenocopy PI3Ka alterations. Constitutive activation of Akt
increases cardiomyocyte size and leads to concentric left ventricle
hypertrophy, while Akt knockout mice display smaller hearts
(Condorelli et al., 2002; Matsui et al., 2002; DeBosch et al.,
2006).
In keeping with a crucial role in cardiac postnatal growth,
PI3Ka promotes physiological hypertrophy and sustains systolic
function in adults. Notably, PI3Ka is protective also in contexts
of heart disease. In a murine model of dilated cardiomyopathy
(DCM), PI3Ka activation mimics the beneficial effects of exercise
training by limiting fetal gene reprogramming and ultimately
prolonging survival, while dominant-negative PI3Ka mice show
reduced lifespan (McMullen et al., 2007). Moreover, ablation
of PI3Ka exacerbates pathological hypertrophy triggered by
either pressure overload or myocardial infarction, whereas PI3Ka
hyperactivation results beneficial in both contexts (McMullen
et al., 2007; Lin et al., 2010). Thus, PI3Ka is essential for
physiological myocardial growth and protects the heart against
pathological remodeling and failure.
Besides the control of cardiac hypertrophy, PI3Ka has been
linked to the regulation of coronary angiogenesis, which is
essential to provide adequate oxygen and nutrient supply to
the myocardium. Studies demonstrate that PI3Ka and PI3Kd,
instead of other isoforms, are central to cardiovasculogenesis
of embryonic stem (ES) cells, in response to VEGF stimulation
(Bekhite et al., 2011). In embryos, PI3Ka deficiency results in
vascular defects and diminished expression of tunica intima
endothelial kinase 2 (Tie2), a receptor tyrosine kinase regulating
vascular development (Lelievre et al., 2005). Accordingly, cardiac-
specific activation of Akt promotes VEGF and angiopoietin-2
expression within cardiomyocytes via a mTOR-dependent
mechanism, and ultimately increases myocardial capillary
density, which is accompanied by physiological hypertrophic
remodeling (Shiojima et al., 2005). Similarly, PTEN inactivation
and Akt overexpression prevent the reduction of myocardial
capillaries induced by pressure overload, thus indicating that
preserved capillary density contributes to the protection against
heart failure observed in these animals (Ceci et al., 2007; Oudit
et al., 2008).
In addition to its involvement in myocardial viability
and anabolism regulation, PI3Ka critically affects cardiac
contractility. Cardiac-specific PI3Ka overexpression results in
enhanced contractility in ex vivo Langendorff-perfused hearts
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FIGURE 1 | Distinct PI3K isoenzymes control specific cardiovascular
processes. Class I PI3Kg is enriched in immune cells and primarily controls
leukocyte infiltration in the myocardium and arteries, a key pathogenic event in
both heart failure and atherosclerosis. Following receptor activation, PI3Kg
catalyzes the production of the lipid second messenger PIP3 which in turn
promotes leukocyte migration and ROS production. On the other hand,
cardiomyocyte PI3Kg is a dual face enzyme which negatively regulates
b-AR/cAMP signaling during the natural history of heart failure, via
kinase-dependent and independent events. By serving as an A-kinase
anchoring protein (AKAP), PI3Kg tethers major PDE isoforms near their activator
PKA. PI3Kg-bound PKA phosphorylates and activates PDEs, which in turn
shape discrete microdomains of cAMP/PKA action, ultimately depressing
cardiac contractility. In physiological conditions, PI3Kg lipid kinase activity is
inhibited by PKA, but escapes PKA-mediated blockade in failing hearts where it
critically contributes to PIP3-dependent b-AR internalization. Conversely, the
other major cardiac PI3K isoform, PI3Ka, is engaged by RTKs and provides
positive control of myocardial contractility and hypertrophy via the PIP3/Akt
classical pathway in response to diverse stimuli, such as pressure overload and
myocardial infarction. Class I PI3Kb instead appears to function not only as a
kinase downstream GPCRs and RTKs, but also as a scaffold protein, which
associates with Rab5 within the Rab5-Vps34-Beclin complexes to activate
cardiac autophagy. Finally, the recently characterized class II PI3K-C2a governs
local PtdIns(3)P production and likely participates to endosomal trafficking within
the cardiovascular system, through yet unexplored mechanisms.
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(Yano et al., 2008), while overexpression of dominant-negative
PI3Ka reduces basal contractility (Liang et al., 2010). Moreover,
both PTEN-null and IGF-1-treated hearts show enhanced L-type
Ca2+ currents (ICa;L), while pharmacological inhibition of either
PI3Ka or Akt reduces Ca2+ currents and contractility (Sun
et al., 2006; Lu et al., 2009), pointing to a crucial role for PI3Ka
in controlling cardiac contractile function. Mechanistically,
PI3Ka modulates the expression of key components of the
calcium-handling machinery, such as the L-type voltage-gated
calcium channel (Cav1.2), the type-2 ryanodine receptor
(RyR) and sarco(endo)plasmic reticulum calcium ATPase 2a
(SERCA2a) (Yano et al., 2008; Lu et al., 2009). Intriguingly, a
recent study reveals that PI3Kb cooperates with PI3Ka to regulate
cardiomyocyte structure and contractility (Wu et al., 2011). Of
note, PI3Ka has also been shown to regulate atrial myocyte
function. PI3Ka activity is significantly lower in patients with
atrial fibrillation, the most common form of cardiac arrhythmia,
than in controls with normal sinus rhythm. Furthermore, PI3Ka
over-expression reduces atrial fibrosis and improves cardiac
conduction in a murine model of dilated cardiomyopathy
(Pretorius et al., 2009).
Overall, these works thus identify beneficial roles for PI3Ka in
the maintenance of cardiovascular homeostasis, via regulation of
cardiomyocyte growth, contractility and coronary angiogenesis.
PI3Kg: Integrating Leukocyte and
Cardiomyocyte Signals During the Natural
History of Heart Disease
Distinct from PI3Ka, PI3Kg is not ubiquitously expressed but
enriched in specific cell subsets, including leukocytes and cardiac
cells. This implies a major role for this isoform in controlling
not only cardiomyocyte pathobiology but also in orchestrating
the inflammatory response associated with cardiovascular injury
(Ghigo et al., 2014).
PI3Kg expression is upregulated both in patients and in mouse
models of atherosclerosis (Fougerat et al., 2008), a chronic disease
where the artery wall thickens as a result of massive leukocyte
infiltration, leading to fat plaque formation and ultimately to
thrombosis and cardiac infarction. Genetic and pharmacological
inhibition of PI3Kg significantly dampens leukocyte recruitment,
primarily macrophages and T cells, to the atherosclerotic lesion,
and improves plaque stabilization in both apolipoprotein E-null
(ApoE / ) (Chang et al., 2007) and low-density lipoprotein
receptor–deficient (LDLR / ) mice (Fougerat et al., 2008).
Notably, PI3Kg-null (PI3Kg / ) bone marrow transplantation
in LDLR /  mice fully recapitulates the protection of whole
body PI3Kg inactivation, thus demonstrating a crucial role for
leukocyte PI3Kg in the atherosclerotic process (Fougerat et al.,
2008). Mechanistically, PI3Kg participates to neuraminidase-
1 (Neu-1) signaling downstream leukocyte elastin receptor
complex (ERC) and crucially governs monocyte migration,
ROS production and the ensuing atherosclerosis development
in response to elastokines (Gayral et al., 2014). Finally, recent
evidence suggests that the atheroprotective effects of PI3Kg
inhibition could be also explained by a major role of the enzyme
in the control of macrophage proliferation, but not M1/M2
polarization, within atherosclerotic plaques (Zotes et al., 2013).
Besides playing a crucial role in atherogenesis, PI3Kg-directed
leukocyte infiltration is amajor determinant of pressure overload-
induced cardiac maladaptive remodeling. Mice expressing a
knock-in catalytically inactive PI3Kg (PI3Kg-KD) or receiving a
PI3Kg-selective inhibitor display reduced fibrosis and preserved
cardiac function up to 16weeks after transverse aortic constriction
(TAC). Intriguingly, wild-type animals carrying PI3Kg-KD bone
marrow are fully protected against TAC-induced dysfunction
while, in the presence of a wild-type immune system, PI3Kg-
KD hearts display prominent leukocyte infiltration and fibrosis.
Nevertheless, these latter chimeric mice display reduced left
ventricular dilation and preserved contractile function compared
to wild-type at later stages after TAC (Damilano et al., 2011), thus
demonstrating that not only leukocyte, but also cardiomyocyte
PI3Kgmediates detrimental effects in hypertensive heart disease.
In cardiomyocytes, PI3Kg counteracts the positive inotropic
action of PI3Ka by affecting b-adrenergic receptor (b-AR)
signaling, a key regulator of myocardial contractility, through
both protein and lipid kinase functions (Perino et al., 2011;
Vasudevan et al., 2011). Notably, PI3Kg lipid kinase activity
is negligible in physiological conditions, owing to both low
expression levels and protein kinase A (PKA)-dependent
phosphorylation, but results dramatically upregulated under
adrenergic stress, such as that occurring in congestive heart
failure (Perino et al., 2011). In this setting, PI3Kg escapes
PKA-mediated inhibition and critically contributes to the
pathological decrease in myocardial b-AR density. PI3Kg
indeed cooperates with GPCR kinase-2 [GRK-2, also known
as b-adrenergic receptor kinase-1 (b-ARK-1)], a key biomarker
molecule upregulated in human heart failure, that by mediating
receptor tail phosphorylation and the following binding by
b-arrestin, interrupts G-protein coupling and initiates the process
of internalization (Woodall et al., 2014). In keeping with these
findings, genetic ablation of PI3Kg and administration of a
selective PI3Kg inhibitor both significantly normalize b-AR
density and improve compromised cardiac contractility of failing
hearts (Perino et al., 2011).
Overall, these works unveil a key role for both leukocyte
and cardiomyocyte PI3Kg in the development of heart failure
and provide proof-of-concept that pharmacological targeting
of PI3Kg activity represents a unique opportunity to treat
cardiovascular diseases through combined actions on both
inflammatory and heart cells.
Class I PI3Ks: Scaffold Roles and
Cross-talk Networks
Although compelling evidence points to key roles of PI3K kinase
activity in cardiac pathophysiology, a new layer of complexity in
the regulation of these enzymes has established in the last decade,
indicating that these proteins function not only as kinases but
also as scaffold proteins (Hirsch et al., 2009). PI3Kg represents
the prototypical PI3K isoenzyme with adaptor activity, exerting
kinase-unrelated functions not only in the myocardium, but also
in other districts including endothelial progenitors (Madeddu
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et al., 2008) and neurons (D’Andrea et al., 2015). In the healthy
heart, PI3Kg acts as an A-kinase anchoring protein (AKAP)
rather than a kinase, tethering major PDE isoforms near their
activator PKA (Perino et al., 2011; Ghigo et al., 2012). In this
context, PI3Kg-bound PKA phosphorylates and activates PDE3
and PDE4, eventually shaping discrete cAMP microdomains and
initiating defined sets of PKA-mediated events downstream of b2-
ARs. Accordingly, PKA-dependent phosphorylation of key Ca2+
handling proteins, a crucial event in the regulation of cardiac
excitation-contraction coupling (Santulli and Marks, 2015), is
dramatically altered in absence of PI3Kg. L-type calcium channel
and phospholamban are hyperphosphorylated in PI3Kg / 
cardiomyocytes and ultimately lead to spontaneous Ca2+ release
events and arrhythmic Ca2+ transients. Intriguingly, PI3Kg-
directed protein complexes are functionally impaired in heart
failure, a condition where ventricular arrhythmia is a major cause
of death (Perino et al., 2011; Ghigo et al., 2012). Thus, deregulation
of PI3Kg scaffold function appears an important component of
heart failure-related arrhythmias.
Besides PI3Kg, also PI3Kb, the other GPCR-activated class
I PI3K isoform, has been reported to exert roles that are
independent of its catalytic activity (Hirsch et al., 2009). In
murine embryonic fibroblasts (MEFs), genetic elimination of
either PI3Kb expression or kinase activity results in defective
internalization of the transferrin receptor (TfR) and the epidermal
growth factor receptor (EGFR; Ciraolo et al., 2008; Jia et al., 2008).
This involves a protein–protein interaction mechanism, likely
relying on the ability of PI3Kb to associate and activate the small
GTPase Rab5, a key regulator of the endocyticmachinery (Ciraolo
et al., 2008). Whether the scaffold activity of PI3Kb affects
endocytic trafficking within cardiomyocytes is still unexplored.
However, recent evidence unveils a crucial role for PI3Kb-
mediated activation of Rab5 in cardiac autophagy induction
(Dou et al., 2010, 2013). This implies that PI3Kb participates
to the autophagic process as part of the Rab5-Vps34-Beclin
complex, thereby favoring Vps34 kinase activity and PtdIns(3)P
production, which in turn is essential for autophagosome
formation. In keeping with this finding, starvation-induced
autophagy is dramatically impaired in PI3Kb-null (PI3Kb / )
hearts. Furthermore, the fact that loss of PI3Kb fully prevents
autophagy during pressure overload indicates that PI3Kb-
dependent control of autophagymay be also relevant to conditions
of heart failure (Dou et al., 2010).
A further level of complexity in PI3K signaling regulation
is provided by the intricate network of cross-talks connecting
different PI3K isoenzymes, downstream of distinct cell surface
receptors. Recent evidence highlights a strict cooperation between
the two GPCR-activated class I PI3K isoforms, PI3Kb and PI3Kg,
in the control of the sympathetic drive in the central nervous
system downstream of the melanocortin 4 receptor (MC4R).
Accordingly, both genetic and pharmacological simultaneous
inhibition of these two isoforms result in reduced Akt-mediated
activation of PDE3B and enhanced cAMP accumulation within
the hypothalamus and the intermediolateral nucleus, ultimately
impinging on white adipose tissue lipolysis (Perino et al.,
2014). Whether PI3Kb- and PI3Kg-dependent adrenergic firing
also affects cardiac function via neuron-cardiomyocyte crosstalk
mechanisms is unclear and further studies are required to clarify
this issue. On the other hand, compelling evidence establishes
a tight connection between cardiomyocyte PI3Kg and the other
major isoform in the myocardium, PI3Ka. For instance, PI3Kg
has been reported to synergize with PI3Ka signaling in the
control of cardiac hypertrophy. Mechanistically, PI3Kg inhibits
GSK-3 activation downstream of the insulin-PI3Ka-Akt pathway,
through a kinase-independentmechanism that primarily prevents
the interaction between the GSK-3 phosphatase, PP2A, and its
activator, PP2A methyltransferase (PPMT-1). This eventually
results in enhanced PI3Ka downstream signaling and cardiac
hypertrophy induction (Mohan et al., 2013). In keeping with a
cardioprotective role of this PI3Ka/PI3Kg synergy, compound
deletion of PI3Ka and PI3Kg genes in the myocardium results in
severe age-dependent cardiomyopathy, while single mutant mice
have preserved systolic and diastolic function up to 1 year of age
(Zhabyeyev et al., 2014).
These works thus emphasize the need of re-thinking the
classical paradigm of PI3K-Akt signaling by considering
the growing multifaceted roles of class I PI3K isoforms in
cardiovascular health and disease.
The Emerging Role of Class II and III PI3K
Isoforms
A further complication in the scenario of PI3K signaling
comes from the recent characterization of less studied isoforms,
including class II and III PI3Ks. The finding that mice lacking
PI3K-C2a display defective cardiac looping and die at early
embryonic stages highlights crucial developmental functions
for this class II isoform (Yoshioka et al., 2012; Franco et al.,
2014). New hints about its role in adult physiology are also
emerging. Endothelial cell-specific PI3K-C2a deletion diminishes
the number of PI(3)P-enriched endosomes, impairs vesicular
trafficking and ultimately leads to defective delivery of VE-
cadherin to endothelial cell junctions and defective junction
assembly. Accordingly, PI3K-C2a disruption correlates with
impaired vascular barrier integrity and higher incidence of
dissecting aortic aneurism formation in response to angiotensin
II infusion. These findings thus unveil PI3K-C2a as a novel
intriguing therapeutic target for vascular diseases (Yoshioka et al.,
2012). Recent evidence highlights a major involvement for this
enzyme also in thrombotic disorders. In vivo PI3K-C2a deficiency
results in unstable thrombi formation, leading to a significant
increase in spontaneous thromboembolism and intermittent
vascular reperfusion in a model of electrolytic injury of the
carotid artery. This phenotype stems from the ability of PI3K-
C2a to modulate internal membrane structure and, eventually,
shear-dependent adhesion of platelets (Mountford et al., 2015).
On the other hand, the cardiovascular impact of other class
II isoforms, PI3K-C2b and PI3K-C2g, is still mysterious and
awaits further investigation. The role of the unique member of
class III PI3Ks in cardiac pathobiology is instead emerging. In
cardiomyocytes, Vps34 critically contributes to both endocytic
and autophagic degradation. Cardiomyocyte-specific genetic
deletion of Vps34 impairs starvation-induced autophagosome
formation and leads to cardiomegaly and contractile dysfunction,
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unveiling an indispensable role for class III PI3K in normal cardiac
function (Jaber et al., 2012). Nonetheless, our understanding of
Vps34 kinase activity is still incomplete and further studies are
required to clarify this issue.
Conclusion
Altogether, these studies underscore both adaptive and
maladaptive actions of PI3K signaling in cardiovascular
homeostasis, with class I PI3Ka having prominent beneficial
effects, including enhanced physiological hypertrophy and
contractility, and PI3Kg mediating detrimental signals leading
to b-AR cascade inhibition. The reasons of this dichotomy
are still not fully understood, but the growing hypothesis
is that PI3K-associated beneficial and deleterious effects
depend on specific upstream/downstream effectors and
on the subcellular compartmentalization of PI3Ks. This
highlights the critical need of elucidating the complexity
of these central signaling pathways to rationally exploit
PI3K hubs for therapeutic intervention design. The recent
discovery of endomembrane-associated isoenzymes and of
new isoform-specific interactors/effectors indicates that efforts
are accumulating in this direction, but further investigation
is required to validate the clinical use of PI3K modulators.
This is urgent given that broad spectrum PI3K inhibitors are
starting to emerge as potential new chemotherapeutic agents,
although their cardiovascular use, efficacy and safety remain
unclear.
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